ATHE - Alterity Therapeutics Limited Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Capital Market Current Price & Safety Score Price: 2.17 USD StockBonds Safety Grade: F Altman Z-Score (Bankruptcy Risk): 1.46 StockBond Score: -4.44 Company Description Alterity Therapeutics Limited an Australian biopharmaceutical firm focuses on the discovery and development of novel drug treatments for various neurological disorders such as Alzheimers Huntingtons and Parkinsons diseases Its prominent experimental therapy ATH434 has completed Phase I clinical trials targeting Parkinsons disease The company is also advancing PBT2 a compound that has successfully undergone Phase IIa clinical testing for Alzheimers disease Established in 1997 the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019 and its main operations are based in Melbourne Australia